Relevance of radiobiological concepts in radionuclide therapy of cancer

References

• Abbas N, Heyerdahl H, Bruland OS, Brevik EM, Dahle J. 2013. Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts. Curr Radiopharm. 6:78–86.
   PubMedGoogle Scholar
• Allen B. 1999. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol. 43:480–486.
   PubMedGoogle Scholar
• Ansoborlo E, Prat O, Moisy P, Auwer CD, Guilbaud P, Carriere M, Gouget B, Duffield J, Doizi D, Vercouter T, et al. 2006. Actinide speciation in relation to biological processes. Biochimie. 88:1605–1618.
   PubMed Web of Science ®Google Scholar
• Apeldoorn L, Voerman HJ, Hoefnagel CA. 1995. Interference of MIBG uptake by medication: a case report. Neth J Med. 46:239–243.
   PubMed Web of Science ®Google Scholar
• Ashrafi SA, Hosseinimehr SJ, Varmira K, Abedi SM. 2012. Radioimmunotherapy with 131I-bevacizumab as a specific molecule for cells with overexpression of the vascular endothelial growth factor. Cancer Biother Radiopharm. 27:420–425.
   PubMed Web of Science ®Google Scholar
• Audicio PF, Castellano G, Tassano MR, Rezzano ME, Fernandez M, Riva E, Robles A, Cabral P, Balter H, Oliver P. 2011. [177Lu]DOTA-anti-CD20: labeling and pre-clinical studies. Appl Radiat Isot. 69:924–928.
   PubMed Web of Science ®Google Scholar
• Aurlien E, Kvinnsland Y, Larsen RH, Bruland OS. 2002. Radiation doses to non-Hodgkin’s lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation. Int J Radiat Biol. 78:133–142.
   PubMed Web of Science ®Google Scholar
• Aurlien E, Larsen RH, Akabani G, Olsen DR, Zalutsky MR, Bruland OS. 2000a. Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry. Int J Radiat Biol. 76:1129–1141.
   PubMed Web of Science ®Google Scholar
• Aurlien E, Larsen RH, Kvalheim G, Bruland OS. 2000b. Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate 211At-rituximab against non-Hodgkin’s lymphoma cells. Br J Cancer. 83:1375–1379.
   PubMed Web of Science ®Google Scholar
• Autsavapromporn N, Plante I, Liu C, Konishi T, Usami N, Funayama T, Azzam EI, Murakami T, Suzuki M. 2015. Genetic changes in progeny of bystander human fibroblasts after microbeam irradiation with X-rays, protons or carbon ions: the relevance to cancer risk. Int J Radiat Biol. 91:62–70.
   PubMed Web of Science ®Google Scholar
• Azzam EI, De Toledo SM, Little JB. 2001. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha-particle irradiated to nonirradiated cells. Proc Natl Acad Sci USA. 98:473–478.
   PubMed Web of Science ®Google Scholar
• Babovic A, Muller C, Bach-Gansmo T. 2013. When should thyroid scintigraphy be performed? Tidsskr Nor Laegeforen. 133:937.
   PubMedGoogle Scholar
• Banerjee S, Pillai MRA, Knapp (Russ) FF. 2015. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev. 115:2934–2974.
   PubMed Web of Science ®Google Scholar
• Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, Mclendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN, et al. 1995. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab’)2 – a preliminary report. J Neurooncol. 24:109–122.
   PubMed Web of Science ®Google Scholar
• Bishayee A, Rao DV, Howell RW. 1999. Evidence for pronounced bystander effects caused by nonuniform distributions of radioactivity using a novel three-dimensional tissue culture model. Radiat Res. 152:88–97.
   PubMed Web of Science ®Google Scholar
• Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJ, Kwekkeboom DJ, De Jong M. 2014. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging. 2:55–66.
   PubMedGoogle Scholar
• Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, Paganelli G. 2014. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thorac Surg Clin. 24:333–349.
   PubMed Web of Science ®Google Scholar
• Bodei L, Kassis AI, Adelstein SJ, Mariani G. 2003. Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications. Cancer Biother Radiopharm. 18:861–877.
   PubMed Web of Science ®Google Scholar
• Bodet-Milin C, Ferrer L, Pallardy A, Eugène T, Rauscher A, Faivre-Chauvet A, Barbet J, Kraeber-Bodéré F. 2013. Radioimmunotherapy of B-cell Non-Hodgkin’s lymphoma. Front Oncol. 3:177.
   PubMedGoogle Scholar
• Boswell CA, Brechbiel MW. 2007. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 34:757–778.
   PubMed Web of Science ®Google Scholar
• Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, Mairs RJ. 2006. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med. 47:1007–1015.
   PubMed Web of Science ®Google Scholar
• Brady D, O’Sullivan JM, Prise KM. 2013. What is the role of the bystander response in radionuclide therapies? Front Oncol. 3:215.
   PubMedGoogle Scholar
• Bryan RA, Jiang Z, Jandl T, Strauss J, Koba W, Onyedika C, Morgenstern A, Bruchertseifer F, Epstein AL, Dadachova E. 2014. Treatment of experimental pancreatic cancer with 213Bismuth-labeled chimeric antibody to single-strand DNA. Expert Rev Anticancer Ther. 14:1243–1249.
   PubMed Web of Science ®Google Scholar
• Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O’Reilly RJ, Scheinberg DA, et al. 2003. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 32:549–556.
   PubMed Web of Science ®Google Scholar
• Bushnell D, O’Dorisio T, O’Dorisio M, Menda Y, Hicks R, Cutsem EV, Baulieu J, Borson-Chazot F, Anthony L, Benson A, et al. 2010. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 28:1652–1659.
   PubMed Web of Science ®Google Scholar
• Buzatu S. 2008. Cellular low-dose effects of ionizing radiation. Riv Biol. 101:279–298.
   PubMed Web of Science ®Google Scholar
• Cai L. 1999. Research of the adaptive response induced by low-dose radiation: where have we been and where should we go? Hum Exp Toxicol. 18:419–425.
   PubMed Web of Science ®Google Scholar
• Calais PJ, Turner JH. 2012. Outpatient 131I-rituximab radoimmunotherapy for non-Hodgkin lymphoma: a study in safety. Clin Nucl Med. 37:732–737.
   PubMed Web of Science ®Google Scholar
• Carlsson J, Forssell AE, Hietala SO, Stigbrand T, Tennvall J. 2003. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol. 66:107–117.
   PubMed Web of Science ®Google Scholar
• Carlsson J, Stigbrand T, Adams GP. 2008. Introduction to radionuclide therapy. In: Carlsson J, Stigbrand T, Adams GP, editors. Targeted radionuclide tumor therapy: biological aspects. Berlin: Springer.
   Google Scholar
• Chang M, Seideman J, Sofou S. 2008. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconjug Chem. 19:1274–1282.
   PubMed Web of Science ®Google Scholar
• Chappell L, Dadachova E, Milenic D, Garmestani K, Wu C, Brechbiel M. 2000. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 27:93–100.
   PubMed Web of Science ®Google Scholar
• Cherel M, Gouard S, Gaschet J, Sai-Maurel C, Bruchertseifer F, Morgenstern A, Bourgeois M, Gestin JF, Bodere FK, Barbet J, et al. 2013. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med. 54:1597–1604.
   PubMed Web of Science ®Google Scholar
• Confino H, Hochman I, Efrati M, Schmidt M, Umansky V, Kelson I, Keisari Y. 2015. Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors. Cancer Immunol Immunother. 64:191–199.
   PubMed Web of Science ®Google Scholar
• Costantini DL, Hu M, Reilly RM. 2008. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm. 23:3–24.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA. 1993. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin’s lymphoma. J Clin Oncol. 11:2021–2029.
   PubMed Web of Science ®Google Scholar
• Dahle J, Abbas N, Bruland OS, Larsen RH. 2011. Toxicity and relative biological effectiveness of alpha-emitting radioimmunoconjugates. Curr Radiopharm. 4:321–328.
   PubMedGoogle Scholar
• Dahle J, Bruland OS, Larsen RH. 2008. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation. Int J Radiat Oncol Biol Phys. 72:186–192.
   PubMed Web of Science ®Google Scholar
• Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. 2013. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin’s lymphoma. Anticancer Res. 33:85–95.
   PubMed Web of Science ®Google Scholar
• Dale R, Carabe-Fernandez A. 2005. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm. 20:47–51.
   PubMed Web of Science ®Google Scholar
• Dauer LT, St Germain J, Williamson MJ, Zanzonico P, Modak S, Cheung NK, Divgi C. 2007. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma. Health Phys. 92:33–39.
   PubMed Web of Science ®Google Scholar
• De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F. 2008. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia. Nucl Med Biol. 35:599–604.
   PubMed Web of Science ®Google Scholar
• Denardo GL. 2005. Concepts in radioimmunotherapy and immunotherapy: radioimmunotherapy from a Lym-1 perspective. Semin Oncol. 32:S27–S35.
   PubMed Web of Science ®Google Scholar
• Desai S, Kobayashi A, Konishi T, Oikawa M, Pandey BN. 2014. Damaging and protective bystander cross-talk between human lung cancer and normal cells after proton microbeam irradiation. Mutat Res. 763–764:39–44.
   PubMed Web of Science ®Google Scholar
• Desai S, Kumar A, Laskar S, Pandey BN. 2013. Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine 61:54–62.
   PubMed Web of Science ®Google Scholar
• Eichholtz-Wirth H, Hietel B. 1994. Cisplatin resistance in mouse fibrosarcoma cells after low-dose irradiation in vitro and in vivo. Br J Cancer. 70:579–584.
   PubMed Web of Science ®Google Scholar
• Enger SA, Hartman T, Carlsson J, Lundqvist H. 2008. Cross-fire doses from beta-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics. Phys Med Biol. 53:1909–1920.
   PubMed Web of Science ®Google Scholar
• Enns L, Bogen KT, Wizniak J, Murtha AD, Weinfeld M. 2004. Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis. Mol Cancer Res. 2:557–566.
   PubMed Web of Science ®Google Scholar
• Feinendegen LE. 1991. Radiation risk of tissue late effects, a net consequence of probabilities of various cellular responses. Eur J Nucl Med. 18:740–751.
   PubMedGoogle Scholar
• Forrer F, Oechslin-Oberholzer C, Campana B, Herrmann R, Maecke HR, Mueller-Brand J, Lohri A. 2013. Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. J Nucl Med. 54:1045–1052.
   PubMed Web of Science ®Google Scholar
• Forrer F, Oechslin-Oberholzer C, Campana B, Maecke H, Mueller-Brand J, Lohri A. 2012. Is there need for radioimmunotherapy? Results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab. Q J Nucl Med Mol Imaging. 56:544–550.
   PubMed Web of Science ®Google Scholar
• Forrer F, Valkema R, Kwekkeboom D, Jong MD, Krenning E. 2007. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 21:111–129.
   PubMed Web of Science ®Google Scholar
• Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, et al. 1998. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res. 4:2691–2700.
   PubMed Web of Science ®Google Scholar
• Friedman NC, Hassan A, Grady E, Matsuoka DT, Jacobson AF. 2014. Efficacy of thyroid blockade on thyroid radioiodine uptake in 123I-mIBG imaging. J Nucl Med. 55:211–215.
   PubMed Web of Science ®Google Scholar
• Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C, Debatin KM, Reske SN. 2007. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res. 67:1950–1958.
   PubMed Web of Science ®Google Scholar
• Friesen C, Lubatschofski A, Kotzerke J, Buchmann I, Reske S, Debatin K. 2003. Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging. 30:1251–1261.
   PubMed Web of Science ®Google Scholar
• Giesel FL, Wulfert S, Zechmann CM, Haberkorn U, Kratochwil C, Flechsig P, Kuder T, Schwartz LH, Bruchertseifer F. 2013. Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy. Exp Oncol. 35:122–126.
   PubMedGoogle Scholar
• Gil’iano N, Konevega LV, Stepanov SI, Semenova EG, Noskin LA. 2007. Internal and external sources of the radiation induce the blocking of the proliferation of the human endothelial cells in culture. G2-block is induced by beta-particle 3H-thymidine and gamma-rays 137Cs. Radiats Biol Radioecol. 47:108–116.
   PubMedGoogle Scholar
• Gil OM, Oliveira N, Rodrigues A, Laires A, Ferreira T, Limbert E, Rueff J. 2002. Possible transient adaptive response to mitomycin C in peripheral lymphocytes from thyroid cancer patients after iodine-131 therapy. Int J Cancer. 102:556–561.
   PubMed Web of Science ®Google Scholar
• Goddu S, Howell R, Rao D. 1994. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med. 35:303–316.
   PubMed Web of Science ®Google Scholar
• Goldsmith S. 2010. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 40:122–135.
   PubMed Web of Science ®Google Scholar
• Gorin J, Guilloux Y, Morgenstern A, Chérel M, Davodeau F, Gaschet J. 2014a. Using α radiation to boost cancer immunity? Oncoimmunology. 3:e954925.
   PubMed Web of Science ®Google Scholar
• Gorin J, Ménager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Chérel M, Davodeau F, et al. 2014b. Antitumor immunity induced after α irradiation. Neoplasia. 16:319–328.
   PubMed Web of Science ®Google Scholar
• Gow M, Seymour C, Byun S, Mothersill C. 2008. Effect of dose rate on the radiation-induced bystander response. Phys Med Biol. 53:119–132.
   PubMed Web of Science ®Google Scholar
• Grunwald F, Ezziddin S. 2010. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 40:153–163.
   PubMed Web of Science ®Google Scholar
• Gupta S, Singla S, Bal C. 2012. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm. 27:593–599.
   PubMed Web of Science ®Google Scholar
• Harun-Or-Rashid M, Asai M, Sun XY, Hayashi Y, Sakamoto J, Murata Y. 2010. Effect of thyroid statuses on sodium/iodide symporter (NIS) gene expression in the extrathyroidal tissues in mice. Thyroid Res. 3:3.
   PubMedGoogle Scholar
• Hdeib A, Sloan A. 2012. Targeted radioimmunotherapy: the role of 131I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas. Future Oncol. 8:659–669.
   PubMed Web of Science ®Google Scholar
• Helbok A, Rangger C, Guggenberg EV, Saba-Lepek M, Radolf T, Thurner G, Andreae F, Prassl R, Decristoforo C. 2012. Targeting properties of peptide-modified radiolabeled liposomal nanoparticles. Nanomedicine. 8:112–118.
   PubMed Web of Science ®Google Scholar
• Herbertson RA, Tebbutt NC, Lee FT, Gill S, Chappell B, Cavicchiolo T, Saunder T, O’Keefe GJ, Poon A, Lee ST, et al. 2014. Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. J Nucl Med. 55:534–539.
   PubMed Web of Science ®Google Scholar
• Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J. 2012. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab. PLoS One. 7:e42345.
   PubMed Web of Science ®Google Scholar
• Hnatowich DJ. 1986. Label stability in serum of four radionuclides on DTPA-coupled antibodies–an evaluation. Int J Rad Appl Instrum B. 13:353–358.
   PubMedGoogle Scholar
• Honore HB, Bentzen SM. 2006. A modelling study of the potential influence of low dose hypersensitivity on radiation treatment planning. Radiother Oncol. 79:115–121.
   PubMed Web of Science ®Google Scholar
• Iagaru A, Mittra E, Ganjoo K, Knox S, Goris M. 2010. 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol. 12:198–203.
   PubMed Web of Science ®Google Scholar
• Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. 2011. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 117:4439–4446.
   PubMed Web of Science ®Google Scholar
• Jain MR, Li M, Chen W, Liu T, De Toledo SM, Pandey BN, Li H, Rabin BM, Azzam EI. 2011. In vivo space radiation-induced non-targeted responses: late effects on molecular signaling in mitochondria. Curr Mol Pharmacol. 4:106–114.
   PubMedGoogle Scholar
• Jamous M, Haberkorn U, Mier W. 2013. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases. Molecules. 18:3379–3409.
   PubMed Web of Science ®Google Scholar
• Jang BS, Lee SM, Kim HS, Shin IS, Razjouyan F, Wang S, Yao Z, Pastan I, Dreher MR, Paik CH. 2012. Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab. Nucl Med Biol. 39:472–483.
   PubMed Web of Science ®Google Scholar
• Janssen ML, Pels W, Massuger LF, Oyen WJ, Boonstra H, Corstens FH, Boerman OC. 2003. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide. Int J Gynecol Cancer. 13:607–613.
   PubMed Web of Science ®Google Scholar
• Jimenez-Mancilla N, Ferro-Flores G, Santos-Cuevas C, Ocampo-Garcia B, Luna-Gutierrez M, Azorin-Vega E, Isaac-Olive K, Camacho-Lopez M, Torres-Garcia E. 2013. Multifunctional targeted therapy system based on 99mTc/177Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells. J Labelled Comp Radiopharm. 56:663–671.
   PubMed Web of Science ®Google Scholar
• Jurcic JG, Larson SM, Sgouros G, Mcdevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, et al. 2002. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 100:1233–1239.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM. 1999. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin’s lymphoma. Clin Cancer Res. 5:3292s–3303s.
   PubMed Web of Science ®Google Scholar
• Kadhim MA, Lee R, Moore SR, MacDonald DA, Chapman KL, Patel G, Prise KM. 2010. Genomic instability after targeted irradiation of human lymphocytes: evidence for inter-individual differences under bystander conditions. Mutat Res. 688:91–94.
   PubMed Web of Science ®Google Scholar
• Kadhim MA, Moore SR, Goodwin EH. 2004. Interrelationships amongst radiation-induced genomic instability, bystander effects, and the adaptive response. Mutat Res. 568:21–32.
   PubMed Web of Science ®Google Scholar
• Kang CS, Song HA, Milenic DE, Baidoo KE, Brechbiel MW, Chong HS. 2013. Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies. Nucl Med Biol. 40:600–605.
   PubMed Web of Science ®Google Scholar
• Kassis A, Adelstein S. 2005. Radiobiologic principles in radionuclide therapy. J Nucl Med. 46:4S–12S.
   PubMed Web of Science ®Google Scholar
• Ke CC, Liu RS, Yang AH, Liu CS, Chi CW, Tseng LM, Tsai YF, Ho JH, Lee CH, Lee OK. 2013. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol Imaging. 40:61–71.
   PubMed Web of Science ®Google Scholar
• Keisari Y, Hochman I, Confino H, Korenstein R, Kelson I. 2014. Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments. Cancer Immunol Immunother. 63:1–9.
   PubMed Web of Science ®Google Scholar
• Kishikawa H, Wang K, Adelstein SJ, Kassis AI. 2006. Inhibitory and stimulatory bystander effects are differentially induced by Iodine-125 and Iodine-123. Radiat Res. 165:688–694.
   PubMed Web of Science ®Google Scholar
• Koi L, Bergmann R, Bruchner K, Pietzsch J, Pietzsch HJ, Krause M, Steinbach J, Zips D, Baumann M. 2014. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiother Oncol. 110:362–369.
   PubMed Web of Science ®Google Scholar
• Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC. 2004. Biodistribution and therapeutic efficacy of 125/131I-, (186)Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med. 45:1224–1232.
   PubMed Web of Science ®Google Scholar
• Kosmas C, Maraveyas A, Gooden CS, Snook D, Epenetos AA. 1995. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J Nucl Med. 36:746–753.
   PubMed Web of Science ®Google Scholar
• Kumar C, Jayakumar S, Pandey BN, Samuel G, Venkatesh M. 2014. Cellular and molecular effects of beta radiation from I-131 on human tumor cells: a comparison with gamma radiation. Curr Radiopharm. 7:138–143.
   PubMedGoogle Scholar
• Kumar C, Pandey BN, Samuel G, Venkatesh M. 2013. Cellular internalization and mechanism of cytotoxicity of 131I-rituximab in Raji cells. J Environ Pathol Toxicol Oncol. 32:91–99.
   PubMed Web of Science ®Google Scholar
• Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY. 2012. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 151:844–850.
   PubMed Web of Science ®Google Scholar
• Larsen R, Borrebaek J, Dahle J, Melhus K, Krogh C, Valan M, Bruland O. 2007. Preparation of Th-227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. Cancer Biother Radiopharm. 22:431–437.
   PubMed Web of Science ®Google Scholar
• Leonard BE, Lucas AC. 2009. LDR brachytherapy: can low dose rate hypersensitivity from the “inverse” dose rate effect cause excessive cell killing to peripherial connective tissues and organs? Br J Radiol. 82:131–139.
   PubMed Web of Science ®Google Scholar
• Li S, Goins B, Hrycushko BA, Phillips WT, Bao A. 2012. Feasibility of eradication of breast cancer cells remaining in postlumpectomy cavity and draining lymph nodes following intracavitary injection of radioactive immunoliposomes. Mol Pharm. 9:2513–2522.
   PubMed Web of Science ®Google Scholar
• Li WP, Ma DS, Higginbotham C, Hoffman T, Ketring AR, Cutler CS, Jurisson SS. 2001. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol. 28:145–154.
   PubMed Web of Science ®Google Scholar
• Lien L, Tvedt B, Heinrich D. 2015. Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride. Int J Urol Nurs. 9:3–13.
   PubMedGoogle Scholar
• Ligiero TB, De Souza Albernaz M, De Carvalho SM, De Oliveira SM, Santos-Oliveira R. 2013. Monoclonal antibodies: application in radiopharmacy. Curr Radiopharm. 6:231–248.
   PubMedGoogle Scholar
• Lim S, Kim E, Woo K, Chung W, Choi C, Lim S. 2006. Induction of G2 arrest and apoptosis of raji cells by continuous low-dose beta irradiation with 188Re-perrhenate. Cancer Biother Radiopharm. 21:314–320.
   PubMed Web of Science ®Google Scholar
• Liu Z, Jin C, Yu Z, Zhang J, Liu Y, Zhao H, Jia B, Wang F. 2010. Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody. Bioconjug Chem. 21:314–318.
   PubMed Web of Science ®Google Scholar
• Loke K, Padhy A, Ng D, Goh A, Divgi C. 2011. Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review. World J Nucl Med. 10:122–138.
   PubMedGoogle Scholar
• Maffioli L, Florimonte L, Costa D, Correia C, Grana C, Luster M, Bodei L, Chinol M. 2015. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer. Quart J Nuclear Med Molec Imaging. 59:420–438.
   PubMed Web of Science ®Google Scholar
• Mairs RJ, Fullerton NE, Zalutsky MR, Boyd M. 2007. Targeted radiotherapy: microgray doses and the bystander effect. Dose Response. 5:204–213.
   PubMedGoogle Scholar
• Matsumoto H, Tomita M, Otsuka K, Hatashita M. 2009. A new paradigm in radioadaptive response developing from microbeam research. J Radiat Res. 50(Suppl. A)A67–79.
   PubMed Web of Science ®Google Scholar
• Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW, et al. 1995. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 85:1122–1131.
   PubMed Web of Science ®Google Scholar
• McLaughlin MF, Robertson D, Pevsner PH, Wall JS, Mirzadeh S, Kennel SJ. 2014. LnPO4 nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy. Cancer Biother Radiopharm. 29:34–41.
   PubMed Web of Science ®Google Scholar
• Meredith R, Wessels B, Knox S. 2008. Risks to normal tissues from radionuclide therapy. Semin Nucl Med. 38:347–357.
   PubMed Web of Science ®Google Scholar
• Monsieurs M, Thierens H, Vral A, Wiele CVD, Ridder LD, Dierckx R. 2000. Adaptive response in patients treated with 131I. J Nucl Med. 41:17–22.
   PubMed Web of Science ®Google Scholar
• Morgan WF. 2002. Genomic instability and bystander effects: a paradigm shift in radiation biology? Mil Med. 167:44–45.
   PubMedGoogle Scholar
• Morgenroth A, Dinger C, Zlatopolskiy BD, Al-Momani E, Glatting G, Mottaghy FM, Reske SN. 2011. Auger electron emitter against multiple myeloma – targeted endo-radio-therapy with 125I-labeled thymidine analogue 5-iodo-4′-thio-2′-deoxyuridine. Nucl Med Biol. 38:1067–1077.
   PubMed Web of Science ®Google Scholar
• Mothersill C, Seymour C. 2006. Radiation-induced bystander and other non-targeted effects: novel intervention points in cancer therapy? Curr Cancer Drug Targets. 6:447–454.
   PubMed Web of Science ®Google Scholar
• Mothersill C, Seymour CB, Joiner MC. 2002. Relationship between radiation-induced low-dose hypersensitivity and the bystander effect. Radiat Res. 157:526–532.
   PubMed Web of Science ®Google Scholar
• Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G, et al. 1995. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res. 1:1447–1454.
   PubMed Web of Science ®Google Scholar
• Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P, Vanderlinden B, Van Dongen GA, Everaert H, et al. 2015. Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging. 42:1304--1314
   PubMed Web of Science ®Google Scholar
• Nagasawa H, Little JB. 1999. Unexpected sensitivity to the induction of mutations by very low doses of alpha-particle radiation: evidence for a bystander effect. Radiat Res. 152:552–557.
   PubMed Web of Science ®Google Scholar
• Naruki Y, Carrasquillo JA, Reynolds JC, Maloney PJ, Frincke JM, Neumann RD, Larson SM. 1990. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. Int J Rad Appl Instrum B. 17:201–207.
   PubMedGoogle Scholar
• O’Donnell RT, Denardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, Denardo GL. 1998. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm. 13:351–361.
   PubMed Web of Science ®Google Scholar
• Ogawa K, Washiyama K. 2012. Bone target radiotracers for palliative therapy of bone metastases. Curr Med Chem. 19:3290–3300.
   PubMed Web of Science ®Google Scholar
• Orlova A, Tran TA, Ekblad T, Karlstrom AE, Tolmachev V. 2010. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging. 37:260–269.
   PubMed Web of Science ®Google Scholar
• Orozco JJ, Balkin ER, Gooley TA, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Hylarides MD, Shadman M, Green DJ, et al. 2014. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model. PLoS One. 9:e113601.
   PubMed Web of Science ®Google Scholar
• Paes F, Serafini A. 2010. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med. 40:89–104.
   PubMed Web of Science ®Google Scholar
• Pandey BN. 2007. Drift from DNA-centric radiation targets: a paradigm shift in radiation biology. Indian J Radiat Res. 4:130–141.
   Google Scholar
• Pandey BN, Gordon DM, De Toledo SM, Pain D, Azzam EI. 2006. Normal human fibroblasts exposed to high- or low-dose ionizing radiation: differential effects on mitochondrial protein import and membrane potential. Antioxid Redox Signal. 8:1253–1261.
   PubMed Web of Science ®Google Scholar
• Pandey BN, Kumar A, Ali M, Mishra KP. 2011. Bystander effect of conditioned medium from low and high doses of gamma-irradiated human leukemic cells on normal lymphocytes and cancer cells. J Environ Pathol Toxicol Oncol. 30:333–340.
   PubMed Web of Science ®Google Scholar
• Pizer B, Papanastassiou V, Hancock J, Cassano W, Coakham H, Kemshead J. 1991. A pilot study of monoclonal antibody targeted radiotherapy in the treatment of central nervous system leukaemia in children. Br J Haematol. 77:466–472.
   PubMed Web of Science ®Google Scholar
• Postema EJ, Frielink C, Oyen WJ, Raemaekers JM, Goldenberg DM, Corstens FH, Boerman OC. 2003. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm. 18:525–533.
   PubMed Web of Science ®Google Scholar
• Pouget J, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, Azria D. 2011. Clinical radioimmunotherapy – the role of radiobiology. Nat Rev Clin Oncol. 8:720–734.
   PubMed Web of Science ®Google Scholar
• Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. 2015. Introduction to radiobiology of targeted radionuclide therapy. Front Med (Lausanne). 2:12.
   PubMedGoogle Scholar
• Preston, RJ. 2005. Radiation biology: concepts for radiation protection. Health Phys. 88:545–556.
   PubMed Web of Science ®Google Scholar
• Prise KM, O’Sullivan JM. 2009. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 9:351–360.
   PubMed Web of Science ®Google Scholar
• Rades D, Wolff C, Nadrowitz R, Breunig C, Schild SE, Baehre M, Meller B. 2009. Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy. Int J Radiat Oncol Biol Phys. 75:1226–1231.
   PubMed Web of Science ®Google Scholar
• Ren R, He M, Dong C, Xie Y, Ye S, Yuan D, Shao C. 2013. Dose response of micronuclei induced by combination radiation of α-particles and γ-rays in human lymphoblast cells. Mutat Res. 741–742:51–56.
   PubMed Web of Science ®Google Scholar
• Ringhoffer M, Blumstein N, Neumaier B, Glatting G, Von Harsdorf S, Buchmann I, Wiesneth M, Kotzerke J, Zenz T, Buck AK, et al. 2005. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study. Br J Haematol. 130:604–613.
   PubMed Web of Science ®Google Scholar
• Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, et al. 2010. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 16:5303–5311.
   PubMed Web of Science ®Google Scholar
• Saintigny Y, Roche S, Meynard D, Lopez B. 2008. Homologous recombination is involved in the repair response of mammalian cells to low doses of tritium. Radiat Res. 170:172–183.
   PubMed Web of Science ®Google Scholar
• Saki M, Toulany M, Sihver W, Zenker M, Heldt JM, Mosch B, Pietzsch HJ, Baumann M, Steinbach J, Rodemann HP. 2012. Cellular and molecular properties of 90Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro. Strahlenther Onkol. 188:823–832.
   PubMed Web of Science ®Google Scholar
• Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, et al. 2009. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 113:2265–2274.
   PubMed Web of Science ®Google Scholar
• Seidl C. 2014. Radioimmunotherapy with alpha-particle-emitting radionuclides. Immunotherapy. 6:431–458.
   PubMed Web of Science ®Google Scholar
• Seregni E, Maccauro M, Chiesa C, Mariani L, Pascali C, Mazzaferro V, De Braud F, Buzzoni R, Milione M, Lorenzoni A, et al. 2014. Treatment with tandem 90Y-DOTA-TATE and 177Lu-DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 41:223–230.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM. 2005. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med. 46:620–633.
   PubMed Web of Science ®Google Scholar
• Short S, Mayes C, Woodcock M, Johns H, Joiner MC. 1999. Low dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol. 75:847–855.
   PubMed Web of Science ®Google Scholar
• Sihver W, Pietzsch J, Krause M, Baumann M, Steinbach J, Pietzsch HJ. 2014. Radiolabeled cetuximab conjugates for EGFR targeted cancer diagnostics and therapy. Pharmaceuticals (Basel). 7:311–338.
   PubMedGoogle Scholar
• Simonsson M, Qvarnstrom F, Nyman J, Johansson KA, Garmo H, Turesson I. 2008. Low-dose hypersensitive gammaH2AX response and infrequent apoptosis in epidermis from radiotherapy patients. Radiother Oncol. 88:388–397.
   PubMed Web of Science ®Google Scholar
• Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, Zhang Z, Reilly RT, Apostolidis C, Morgenstern A, et al. 2008. 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res. 68:3873–3880.
   PubMed Web of Science ®Google Scholar
• Stevens PL, Oluwole O, Reddy N. 2012. Advances and application of radioimmunotherapy in non-Hodgkin lymphoma. Am J Blood Res. 2:86–97.
   PubMedGoogle Scholar
• Stinchcomb T, Roeske J. 1992. Analytic microdosimetiy for radloimmuno therapeutic alpha emitters. Med Phys. 19:1385.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, et al. 2013. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 19:5182–5191.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Leggett RW. 2003. A generic biokinetic model for predicting the behaviour of the lanthanide elements in the human body. Radiat Prot Dosimetry. 105:193–198.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Stradling GN, Menetrier F. 2003. Biokinetics of radionuclides and treatment of accidental intakes. Radiat Prot Dosimetry. 105:637–640.
   PubMed Web of Science ®Google Scholar
• Tome WA, Howard SP. 2007. On the possible increase in local tumour control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule. Br J Radiol. 80:32–37.
   PubMed Web of Science ®Google Scholar
• Trott KR. 2001. Non-targeted radiation effects in radiotherapy – roles of radiation-induced genomic instability and of the bystander effect in cancer cure by radiotherapy. Acta Oncol. 40:976–980.
   PubMed Web of Science ®Google Scholar
• Upadhyay G, Singh R, Agarwal G, Mishra SK, Pal L, Pradhan PK, Das BK, Godbole MM. 2003. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat. 77:157–165.
   PubMed Web of Science ®Google Scholar
• Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. 2005. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 11:7195s–7200s.
   PubMed Web of Science ®Google Scholar
• Vandenbulcke K, De Vos F, Offner F, Philippe J, Apostolidis C, Molinet R, Nikula TK, Bacher K, De Gelder V, Vral A, et al. 2003. In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging. 30:1357–1364.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. 2007. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 26:3699–3703.
   PubMed Web of Science ®Google Scholar
• Wroblewski VJ. 1991. Mechanism of deiodination of 125I-human growth hormone in vivo. Relevance to the study of protein disposition. Biochem Pharmacol. 42:889–897.
   PubMed Web of Science ®Google Scholar
• Wulbrand C, Seidl C, Gaertner FC, Bruchertseifer F, Morgenstern A, Essler M, Senekowitsch-Schmidtke R. 2013. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLoS One. 8:e64730.
   PubMed Web of Science ®Google Scholar
• Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. 2002. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA. 99:13765–13770.
   PubMed Web of Science ®Google Scholar
• Yong K, Brechbiel M. 2011. Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans. 40:6068–6076.
   PubMed Web of Science ®Google Scholar
• Zalutsky MR, Stabin MG, Larsen RH, Bigner DD. 1997. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Nucl Med Biol. 24:255–261.
   PubMed Web of Science ®Google Scholar